12:32 PM
 | 
Apr 13, 2017
 |  BC Extra  |  Company News

BMS out-licenses programs to Biogen, Roche

Bristol-Myers Squibb Co. (NYSE:BMY) said Thursday it out-licensed a pair of programs to Biogen Inc. (NASDAQ:BIIB) and Roche (SIX:ROG; OTCQX:RHHBY). Spokesperson Chrissy Trank told BioCentury the deals end BMS's clinical development of therapies for genetically defined diseases.

Biogen received rights to BMS-986168, a mAb targeting microtubule-associated protein tau (tau;...

Read the full 247 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >